Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3918 in complement inhibitor-naive or recently untreated PNH
2018-002734-20Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pozelimab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Co-primary endpoints and Reduction in intravascular hemolysis over 26 weeks. Started Mar 2019; status: completed.
02
Drugs
pozelimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2018-002734-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002734-20.